AZN
Astrazeneca plc
Stock NYSE – Stock Market Prices, News & Analysis
Astrazeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of drugs for various therapeutic areas.
Astrazeneca plc
AZN
Astrazeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of drugs for various therapeutic areas.
Price history of Astrazeneca plc
Price history of Astrazeneca plc
Performance & Momentum
AstraZeneca Exits Nasdaq-100, Replaced by Walmart
AstraZeneca plc (NASDAQ: AZN) will be removed from the Nasdaq-100 index effective January 20, 2026, with Walmart Inc. taking its place. This change follows Walmart's listing transfer to the Nasdaq, triggering a significant rebalancing of index funds. Meanwhile, Berenberg Bank maintains a buy rating on AstraZeneca following positive clinical trial results, affirming the company's medium-term growth potential despite the index exit. AstraZeneca's partnership with Tempus AI also highlights its commitment to innovation in precision medicine, supporting its strategic outlook.
Strategic Analysis
Astrazeneca plc • 2026
AstraZeneca positions itself as a global leader in biopharmaceuticals, specializing in the research and development of innovative treatments, particularly in oncology. Its strategy is based on a strong capacity for innovation and a diversified geographical presence that supports its long-term growth.
Strengths
- Portfolio of high-potential drugs, especially in oncology
- Advanced R&D capabilities fostering therapeutic innovation
- Balanced global presence enhancing resilience against local market pressures
Weaknesses
- Recent exit from the Nasdaq-100 which may signal competitive pressure or sector repositioning
- Highly regulated sector impacting the speed of commercialization for new molecules
Momentum
AstraZeneca's momentum remains strong, driven by positive performance over several time horizons, despite the recent exclusion from the Nasdaq-100. This development could prompt the company to strengthen its strategic initiatives to regain increased visibility with investors, while continuing to capitalize on its growth momentum in key therapeutic segments.
Similar stocks to Astrazeneca plc
Recent News
Astrazeneca plc
IMFINZI Approved in US for Early Gastric Cancers
4 months agoAstraZeneca received US approval for IMFINZI® (durvalumab) combined with FLOT chemotherapy to treat early and locally advanced gastric and gastroesophageal cancers. This approval opens a promising new therapeutic market for the company. Meanwhile, US regulations are significantly lowering prices for some drugs, which could indirectly impact the pharmaceutical sector. Despite this, IMFINZI's approval strengthens AstraZeneca's oncology position, offering positive medium-term prospects.
AstraZeneca reports positive neuromyelitis optica results
6 months agoAstraZeneca revealed that its Alexion unit will present encouraging final results from a Phase III study on neuromyelitis optica at the ECTRIMS 2025 congress. Despite these positive announcements, the stock remains steady with a slight daily decline of -0.8%, reflecting the market's cautious wait for the official full data release.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
